LFM-A13 - CAS 62004-35-7

INQUIRY Add to cart

For Research Use Only | Not For Clinical Use

CAT	AP62004357
CAS	62004-35-7
Structure
Molecular Weight	360.00

Description	A potent, cell-permeable, reversible, substrate competitive, and specific inhibitor of Bruton's Tyrosine Kinase (BTK; IC₅₀ = 17.2 µM for human BTK in vitro and IC₅₀ = 2.5 µM for recombinant BTK).
Solubility	DMSO: 200 mg/mL
Assay	≥97% (HPLC)
Color	light brown
Form	solid; protect from light
Size	5MG
Storage Conditions	+2C to +8C

In Vivo Toxicity and Antithrombotic Profile of the Oral Formulation of the Antileukemic Agent, LFM-A13-F

Heather E Tibbles, Peter Samuel, Doug Erbeck, Sandeep Mahajan, Fatih M Uckun

Arzneimittelforschung. 2004;54(6):330-9.

PMID: 15281619

Large-scale Synthesis of GMP Grade alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) Propenamide (LFM-A13), a New Anti-Cancer Drug Candidate

Darin DuMez, Taracad K Venkatachalam, Fatih M Uckun

Arzneimittelforschung. 2007;57(3):155-63.

PMID: 17469650

Preclinical Toxicity and Pharmacokinetics of the Bruton's Tyrosine Kinase-Targeting Anti-Leukemic Drug Candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) Propenamide (LFM-A13)

Fatih M Uckun, Heather Tibbles, Taracad Venkatachalam, Darin DuMez, Douglas Erbeck

Arzneimittelforschung. 2007;57(1):31-46.

PMID: 17341007

* Products or Services Interested: LFM-A13 - CAS 62004-35-7 (62004-35-7)
* Your question
* Name
* Email
Verification Code

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.

Online Inquiry